Related Experiment Video
Updated: Jul 30, 2025
Optimized Analysis of In Vivo and In Vitro Hepatic Steatosis
Published on: March 11, 2017
Fatal hepatic failure following atorvastatin treatment: A case report
Huajun Wang1, Shiyi Liu, Chenjie Zhou
1Department of Intensive Care Unit, The Affiliated People's Hospital of Ningbo University, Ningbo City, Zhejiang Province, P. R. China.
Insights
Atorvastatin, a common cholesterol drug, can cause rare but severe liver injury. A patient experienced fatal liver and kidney failure within hours of restarting atorvastatin, highlighting the serious risks of statin-induced idiosyncratic liver injury.
Area of Science:
- Pharmacology
- Hepatology
- Clinical Medicine
Background:
- Atorvastatin is a widely prescribed statin for managing hypercholesterolemia and reducing cardiovascular disease risk.
- While generally safe, rare instances of fatal liver failure associated with atorvastatin have been documented, particularly with short incubation periods.
Observation:
- A 63-year-old male presented with chest pain and developed acute liver dysfunction within 24 hours of initiating atorvastatin (20 mg).
- Upon rechallenging with atorvastatin 15 days later, the patient rapidly progressed to multiple organ failure, including liver and renal failure, within 16 hours.
Findings:
- Pathological examination revealed focal inflammatory necrosis; viral and autoimmune markers were negative, consistent with drug-induced liver injury.
- Despite intensive organ support, including artificial liver therapy and continuous renal replacement therapy, the patient died 18 days after admission.
Implications:
- This case underscores the potential for severe idiosyncratic reactions to atorvastatin, even with brief exposure.
- It emphasizes the critical need for vigilant monitoring of liver function in patients receiving statin therapy, as severe outcomes can occur unpredictably.
Rationale:
Atorvastatin is a commonly used statin for the treatment of hypercholesterolemia in people at high risk for coronary, cerebrovascular, and peripheral artery disease. However, fatal liver failure due to atorvastatin treatment has been rarely reported, especially during the very short incubation period.
Patient Concerns:
A 63-year-old male patient was admitted due to unexplained chest pain. After admission, his liver function had decreased < 24 hours after taking 20 mg tablets of atorvastatin due to lacunar infarction, which was improved after drug withdrawal. The treatment regimen was restarted 15 days later, but within 16 hours, the patient developed multiple organ failure, including liver failure and renal failure.
Diagnoses:
The pathological results after 7 days indicated focal inflammatory necrosis, virus and autoimmune correlation tests were negative, which did not rule out drug-induced liver injury. Interventions: receiving artificial liver therapy, continuous renal replacement therapy and other organ support treatment.
Outcomes:
The patient died 18 days after admission.
Lessons:
Statin idiosyncratic liver injury is very rare, but the consequences can be serious.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:16Hepatic Drug Excretion: Influencing Factors
01:26Atherosclerosis III: Management
01:09Hepatic Drug Clearance: Effect of Protein Binding
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
01:26Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
01:17Hepatic Drug Excretion: Enterohepatic Cycling
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...